These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 10607689

  • 1. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease.
    Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I, Lu JG, Gajewski J, Durett A, Cleary K, Champlin R, Andersson BS, Light S.
    Blood; 2000 Jan 01; 95(1):83-9. PubMed ID: 10607689
    [Abstract] [Full Text] [Related]

  • 2. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab.
    Willenbacher W, Basara N, Blau IW, Fauser AA, Kiehl MG.
    Br J Haematol; 2001 Mar 01; 112(3):820-3. PubMed ID: 11260089
    [Abstract] [Full Text] [Related]

  • 3. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor.
    Anasetti C, Hansen JA, Waldmann TA, Appelbaum FR, Davis J, Deeg HJ, Doney K, Martin PJ, Nash R, Storb R.
    Blood; 1994 Aug 15; 84(4):1320-7. PubMed ID: 8049447
    [Abstract] [Full Text] [Related]

  • 4. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial.
    Lee SJ, Zahrieh D, Agura E, MacMillan ML, Maziarz RT, McCarthy PL, Ho VT, Cutler C, Alyea EP, Antin JH, Soiffer RJ.
    Blood; 2004 Sep 01; 104(5):1559-64. PubMed ID: 15138163
    [Abstract] [Full Text] [Related]

  • 5. Allogeneic peripheral blood stem cell transplant (PBSCT) using anti-IL2 receptor antibody Daclizumab for the prevention of acute graft versus host disease in steroid refractory Diamond Blackfan anaemia: a case report.
    Shamsi TS, Irfan M, Farzana T, Ansari SH, Ahmad G, Shakoor N, Baig MI.
    J Pak Med Assoc; 2005 Oct 01; 55(10):454-5. PubMed ID: 16304857
    [Abstract] [Full Text] [Related]

  • 6. CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation.
    Locke FL, Pidala J, Storer B, Martin PJ, Pulsipher MA, Chauncey TR, Jacobsen N, Kröger N, Walker I, Light S, Shaw BE, Beato F, Laport GG, Nademanee A, Keating A, Socie G, Anasetti C.
    Biol Blood Marrow Transplant; 2017 Mar 01; 23(3):405-411. PubMed ID: 28007665
    [Abstract] [Full Text] [Related]

  • 7. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.
    Srinivasan R, Chakrabarti S, Walsh T, Igarashi T, Takahashi Y, Kleiner D, Donohue T, Shalabi R, Carvallo C, Barrett AJ, Geller N, Childs R.
    Br J Haematol; 2004 Mar 01; 124(6):777-86. PubMed ID: 15009066
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prophylactic effects of interleukin-2 receptor antagonists against graft-versus-host disease following unrelated donor peripheral blood stem cell transplantation.
    Fang J, Hu C, Hong M, Wu Q, You Y, Zhong Z, Li W, Zou P, Hu Y, Xia L.
    Biol Blood Marrow Transplant; 2012 May 01; 18(5):754-62. PubMed ID: 21963619
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation.
    Koch M, Niemeyer G, Patel I, Light S, Nashan B.
    Transplantation; 2002 May 27; 73(10):1640-6. PubMed ID: 12042653
    [Abstract] [Full Text] [Related]

  • 12. Long-term follow-up of children treated with daclizumab for steroid-refractory gastrointestinal GvHD in a prospective study.
    Hamidieh AA, Hadjibabaie M, Ghehi MT, Jalili M, Hosseini A, Pasha F, Behfar M, Ghavamzadeh A.
    Pediatr Transplant; 2012 Sep 27; 16(6):664-9. PubMed ID: 22738324
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. New immunosuppressants in BMT/GVHD.
    Basara N, Günzelmann S, Willenbacher W, Fauser AA, Kiehl MG.
    Transplant Proc; 2001 May 27; 33(3):2220-2. PubMed ID: 11377507
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab.
    Pascual J, Marcén R, Ortuño J.
    Nephrol Dial Transplant; 2001 Sep 27; 16(9):1756-60. PubMed ID: 11522853
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-Versus-Host Disease.
    Shen MZ, Li JX, Zhang XH, Xu LP, Wang Y, Liu KY, Huang XJ, Hong SD, Mo XD.
    Front Immunol; 2021 Sep 27; 12():749266. PubMed ID: 34621279
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.